The Pharma Data
DECEMBER 13, 2020
.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. He received his B.S.
Drug Discovery World
FEBRUARY 12, 2024
In 2024, we can expect another wave of innovative new drugs to be developed using the technology, given that the AI-fuelled small molecule discovery pipeline is growing by almost 40% annually.” It is becoming more broadly acknowledged that AI is set to transform one of the most promising yet under-utilised fields of omics – 3D genomics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JUNE 5, 2023
New approaches to partnering In this event in the Biotech track, Clive Cookson, Science Editor at the Financial Times, interviewed John McDonald, Corporate Vice President, Global R&D Business Development, Novo Nordisk. I consider one of my responsibilities to advocate the advent of a new era for 3D genomics.
The Pharma Data
JUNE 7, 2023
Acuitas’ proprietary LNP technology is used in multiple vaccines and therapeutics in clinical development and was also used in some of the COVID-19 vaccines that were approved and administered to people in 180 countries. LNPs are spheric drug delivery bodies which can be equipped with therapeutic payloads for intracellular delivery.
Pharmaceutical Technology
DECEMBER 22, 2022
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. Deerfield and Illumina win the Research and Development award this year due to their commitment to research into AI-driven therapies. Innovation.
The Pharma Data
NOVEMBER 3, 2020
According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. Commenting on the announcement, Daniel Gruskin, M.D., LogicBio is headquartered in Lexington, Mass.
The Pharma Data
JANUARY 12, 2021
Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. As a result, the company settled on four areas of focus – iPSC, allogenic CAR-T, genome mutations and gene editing. Photo courtesy of Bayer. We have set the bar high.
Expert insights. Personalized for you.
40 
Let's personalize your content